Abrocitinib bests placebo for treatment of atopic dermatitis
Study of NCOA3 yields novel findings of melanoma progression
25 March 2021Legal recreational cannabis tied to more claims of self-harm in younger men
25 March 2021Abrocitinib bests placebo for treatment of atopic dermatitis
(HealthDay)—For moderate-to-severe atopic dermatitis, the oral Janus kinase 1 (JAK1) inhibitor abrocitinib at 200 mg or 100 mg once daily results in significantly greater reductions in signs and symptoms versus placebo, according to a study published in the March 25 issue of the New England Journal of Medicine.
